Girentuximab Completed Phase 2 Trials for metastatic Clear Cell Renal Cell Carcinoma (ccRCC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02002312
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer